Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BORID for Relapsed/Refractory Mantle Cell Lymphoma
NCT00261612Phase 2Unknown
- Sponsor
- Medical University of Vienna
- Start
- Jan 2005
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in mantle cell lymphoma (MCL), sponsored by Medical University of Vienna. Primary endpoint: Response Rate. Status: unknown.
02
Drugs
bortezomib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00261612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00261612.